Ignite Creation Date:
2024-05-06 @ 8:03 AM
Last Modification Date:
2024-10-26 @ 11:55 AM
Study NCT ID:
NCT02659657
Status:
UNKNOWN
Last Update Posted:
2020-10-01
First Post:
2016-01-08
Brief Title:
Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
Prophylaxis Roles of Low Dose of IL-2 Treatment on GVHD After Haploidentical Transplantation
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation HBMT on hematological malignancies are well establishedThe aim of this prospective cohort trial is to determine if acute graft-versus-host disease aGVHD could be decreased with IL2 therapy post HBMT
Detailed Description:
The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation HBMT on hematological malignancies are well establishedThe aim of this prospective cohort trial is to determine if acute graft-versus-host disease aGVHD could be decreased with IL2 therapy post HBMTlow dose of IL-2 40 million Um2 will be administered from WBC engraftment to day 90 post haploidentical transplantation IL-2 will be administered three times a week
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None